Skip to main content

Table 1 Patient data

From: Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid

Patients

Number

1

2

3

4

5

6

7

8

9

Sex

F

F

F

F

M

F

F

F

F

Age of onset (years)

7

10

13

13

13

18

20

18

26

Follow-up (months)

25

12

26

13

1

1

6

12

5

Clinical features at the disease peak

Psychiatric features

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Cognitive dysfunction

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Seizures

Yes

No

Yes

Yes

No

Yes

Yes

Yes

Yes

Movement disorder

Yes

Yes

No

Yes

Yes

No

No

Yes

No

Autonomic dysfunction

Yes

No

No

No

No

No

No

Yes

No

Coma

Yes

No

No

No

No

No

No

Yes

No

Laboratory features at the disease diagnosis

MRI changes

No

No

No

Yes

No

No

No

No

Yes

EEG changes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Disease course and therapy

Progression (days)a

28

15

28

17

6

16

30

29

29

Time to therapy (days)b

6

15

49

21

4

320

60

21

29

Recovery (days)c

750

43

91

72

30

320

36

150

85

Therapyd

IVIG, CS, PE, RTX, CPA, IA, alemtuzumab, MTX, MMF

PE, CS, IVIG

PE, CS, IVIG

PE, CS, IVIG

CS, IVIG

PE, IVIG, CS

CS, IVIG

PE, IVIG, CS, RTX

PE, CS, CPA

  1. This table summarizes the clinical, laboratory and follow-up data of nine patients with non-paraneoplastic anti-NMDAR encephalitis who were included in this study. Our clinical study was focused on the dynamic course of the disease over time (in days after the onset of the first disease symptom): atime to the peak in disease severity (all of the patients reached their disease severity peak within 30 days, and despite receiving immunotherapy, patients nos. 1 and 8 progressed to a mRS of 5); btime to first therapy administration (all of the patients except for patient no. 6 received therapy within 60 days); and ctime to clinical improvement to a mRS ≤2 (the recovery time varied between the patients: median 85 days, range 30–750 days; patient no. 6 had a mRS of 2 at the time of diagnosis). dThe therapy summary is indicated as follows: CPA cyclophosphamide, CS corticosteroids, IA immunoadsorption, MMF mycophenolate mophetil, MTX methotrexate, PE plasma exchange, RTX rituximab